ALZAMEND NEURO INC

Alzamend Neuro’s insider purchase of Series D convertible preferred shares reveals a bullish bet on its neuro‑therapeutics pipeline, offering a conversion premium, liquidation preference and risk‑mitigated upside amid regulatory and Nasdaq complianc…

Alzamend Neuro’s insider option activity signals strong executive confidence, aligning leadership incentives with shareholder value ahead of its Series D funding and drug‑development milestones.